ACTIVE INGREDIENT: Letrozole
STRENGTH & PACK SIZE & GMS CODES:
2.5 mg Film-Coated Tablets x 30 ~ 24525
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breastcancer.
Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer. Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal
endocrine status, who have previously been treated with anti-oestrogens.
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.
Efficacy has not been demonstrated in patients with hormone receptor negative breast cancer.